ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
0
views
0
references
Top references
cited by
3
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,453
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up
Author(s):
C. Barale
,
K Bonomo
,
C. Frascaroli
,
A. Morotti
,
A Guerrasio
,
F Cavalot
Publication date:
2020
Journal:
Nutr Metab Cardiovas Dis NMCD
Read this article at
ScienceOpen
PubMed
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Cardiovascular Innovations and Applications
Author and article information
Journal
PubMed ID::
31653513
ScienceOpen disciplines:
General medicine
,
Medicine
,
Geriatric medicine
,
Transplantation
,
Cardiovascular Medicine
,
Anesthesiology & Pain management
Data availability:
ScienceOpen disciplines:
General medicine
,
Medicine
,
Geriatric medicine
,
Transplantation
,
Cardiovascular Medicine
,
Anesthesiology & Pain management
Comments
Comment on this article
Sign in to comment
Similar content
2,453
Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Authors:
Delphine Allard
,
Sabine Amsellem
,
Marianne Abifadel
…
PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship
Authors:
Raimondo Feminò
,
Giovanni Feminò
,
Attilio Cavezzi
…
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial
Authors:
RP GIUGLIANO
,
TR Peterson
,
G. PARK
See all similar
Cited by
3
Dose-dependent effects of anthocyanin supplementation on platelet function in subjects with dyslipidemia: A randomized clinical trial
Authors:
Zezhong Tian
,
Kongyao Li
,
Die Fan
…
Anthocyanin on platelet function in people with dyslipidaemia
Authors:
Ayodele A Ogunleye
Clinical Significance of PCSK9 and Soluble P-selectin in Predicting Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome
Authors:
Yao Yao
,
Qining Qiu
,
Xiaoye Li
…
See all cited by